Nektar down 24% as trials spell the end for Opdivo and bempeg combo

19 April 2022

US biotech Nektar Therapeutics (Nasdaq: NKTR) lost 23% of its market value on Monday.

This followed the announcement of a decision made based on results from pre-planned analyses of two late-stage studies of bempegaldesleukin (bempeg) in combination with Bristol Myers Squibb’s (NYSE: BMY) Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer.

The companies have jointly decided to end the global clinical development program for bempeg in combination with Opdivo. These studies and all other ongoing studies in the program will be discontinued.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK